1. |
Buehl W, Sacu S, Schmidt-Erfurth U. Retinal vein occlusions[J]. Dev Ophthalmol, 2010, 46: 54-72. DOI: 10.1159/000320009.
|
2. |
Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern®[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
|
3. |
Scott IU, Campochiaro PA, Newman NJ, et al. Retinal vascular occlusions[J]. Lancet, 2020, 396(10266): 1927-1940. DOI: 10.1016/S0140-6736(20)31559-2.
|
4. |
Sanborn GE, Magargal LE. Characteristics of the hemispheric retinal vein occlusion[J]. Ophthalmology, 1984, 91(12): 1616-1626. DOI: 10.1016/s0161-6420(84)34111-2.
|
5. |
Hayreh SS, Hayreh MS. Hemi-central retinal vein occulsion. Pathogenesis, clinical features, and natural history[J]. Arch Ophthalmol, 1980, 98(9): 1600-1609. DOI: 10.1001/archopht.1980.01020040452011.
|
6. |
Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J]. Surv Ophthalmol, 2018, 63(6): 816-850. DOI: 10.1016/j.survophthal.2018.04.005.
|
7. |
Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy. Baseline findings[J]. Online J Curr Clin Trials, 1993, 14: 1.
|
8. |
A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report[J]. Ophthalmology, 1995, 102(10): 1434-1444. DOI: 10.1016/S0161-6420(95)30848-2.
|
9. |
Nicholson L, Vazquez-Alfageme C, Patrao NV, et al. Retinal nonperfusion in the posterior pole is associated with increased risk of neovascularization in central retinal vein occlusion[J]. Am J Ophthalmol, 2017, 182: 118-125. DOI: 10.1016/j.ajo.2017.07.015.
|
10. |
Thomas AS, Thomas MK, Finn AP, et al. Use of the ischemic index on widefield fluorescein angiography to characterize a central retinal vein occlusion as ischemic or nonischemic[J]. Retina, 2019, 39(6): 1033-1038. DOI: 10.1097/IAE.0000000000002126.
|
11. |
An W, Han J. Research progress of UWFFA and OCTA in retinal vein occlusion: a review[J]. Eur J Ophthalmol, 2021, 31(6): 2850-2855. DOI: 10.1177/11206721211027411.
|
12. |
Tsai G, Banaee T, Conti FF, et al. Optical coherence tomography angiography in eyes with retinal vein occlusion[J]. J Ophthalmic Vis Res, 2018, 13(3): 315-332. DOI: 10.4103/jovr.jovr_264_17.
|
13. |
Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial[J]. Arch Ophthalmol, 1986, 104(1): 34-41. DOI: 10.1001/archopht.1986.01050130044017.
|
14. |
赵明威, 苗恒. 视网膜静脉阻塞诊疗重在全病程管理[J]. 中华眼科杂志, 2020, 56(4): 246-249. DOI: 10.3760/cma.j.cn112142-20200207-00052.Zhao MW, Miao H. Whole course management is the key to retinal vein occlusion[J]. Chin J Ophthalmol, 2020, 56(4): 246-249. DOI: 10.3760/cma.j.cn112142-20200207-00052.
|
15. |
Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome-a systematic review[J]. Med Sci Monit, 2012, 18(8): 138-144. DOI: 10.12659/msm.883260.
|
16. |
Tang Y, Cheng Y, Wang S, et al. Review: the development of risk factors and cytokines in retinal vein occlusion[J/OL]. Front Med (Lausanne), 2022, 9: 910600[2022-06-15]. https://pubmed.ncbi.nlm.nih.gov/35783660/. DOI: 10.3389/fmed.2022.910600.
|
17. |
Chen TY, Uppuluri A, Zarbin MA, et al. Risk factors for central retinal vein occlusion in young adults[J]. Eur J Ophthalmol, 2021, 31(5): 2546-2555. DOI: 10.1177/1120672120960333.
|
18. |
Orskov M, Vorum H, Bjerregaard Larsen T, et al. A review of risk factors for retinal vein occlusions[J]. Expert Rev Cardiovasc Ther, 2022, 20(9): 761-772. DOI: 10.1080/14779072.2022.2112667.
|
19. |
Romano F, Lamanna F, Gabrielle PH, et al. Update on retinal vein occlusion[J]. Asia Pac J Ophthalmol (Phila), 2023, 12(2): 196-210. DOI: 10.1097/APO.0000000000000598.
|
20. |
Steinbrugger I, Haas A, Maier R, et al. Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion[J]. Mol Vis, 2009, 15: 609-618.
|
21. |
Jaulim A, Ahmed B, Khanam T, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature[J]. Retina, 2013, 33(5): 901-910. DOI: 10.1097/IAE.0b013e3182870c15.
|
22. |
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
|
23. |
Sohn JH, Song SJ. Arteriovenous sheathotomy for persistent macular edema in branch retinal vein occlusion[J]. Korean J Ophthalmol, 2006, 20(4): 210-214. DOI: 10.3341/kjo.2006.20.4.210.
|
24. |
Chen Y, Sharma T, Li X, et al. Ranizumab versus vitipofoen photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study[J]. Retina, 2019, 39(10): 1985-1994. DOI: 10.1097/IAE.0000000000002292.
|
25. |
Wei W, Weisberger A, Zhu L, et al. Efficacy and safety of Ranibizumab in Asian patients with branch retinal vein occlusion: results from the randomized BLOSSOM Study[J]. Ophthalmol Retina, 2020, 4(1): 57-66. DOI: 10.1016/j.oret.2019.08.001.
|
26. |
Sun Z, Zhou H, Lin B, et al. Efficacy and safety of intravitreal Conbercept injections in macular edema secondary to retinal vein occlusion[J]. Retina, 2017, 37(9): 1723-1730. DOI: 10.1097/IAE.0000000000001404.
|
27. |
Chen X, Hu TM, Zuo J, et al. Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections[J]. BMC Ophthalmol, 2020, 20(1): 225. DOI: 10.1186/s12886-020-01494-x.
|
28. |
Zeng HY, Liu Q, Li XX, et al. One-year efficacy of intravitreal conbercept injection for macular oedema secondary to central retinal vein occlusion in Chinese patients[J]. Eye (Lond), 2020, 34(8): 1459-1464. DOI: 10.1038/s41433-020-0827-y.
|
29. |
Zhong P, He M, Yu H, et al. A meta-analysis of cardiovascular events associated with intravitreal anti-VEGF treatment in patients with retinal vein occlusion[J]. Curr Eye Res, 2020, 45(5): 615-622. DOI: 10.1080/02713683.2019.1687727.
|
30. |
Chengdu Kanghong Biotech Co. L. 2017. Conbercept ophthalmic injection for patients of central retinal vein occlusion (CRAVE)[EB/OL]. [2022-07-13]. https://www.clinicaltrials.gov/ct2/show/study/NCT03223714.
|
31. |
Chengdu Kanghong Biotech Co. L. 2017. Conbercept ophthalmic injection for patients with macular edema caused by branch retinal vein occlusion (BRAVE)[EB/OL]. [2022-06-13]. https://www.clinicaltrials.gov/ct2/show/study/NCT03108352.
|
32. |
Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis[J/OL]. BMJ Open, 2015, 5(6): e007527[2015-06-05]. https://pubmed.ncbi.nlm.nih.gov/26048209/. DOI: 10.1136/bmjopen-2014-007527.
|
33. |
Sangroongruangsri S, Ratanapakorn T, Wu O, et al. Comparative efficacy of Bevacizumab, Ranibizumab, and Aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis[J]. Expert Rev Clin Pharmacol, 2018, 11(9): 903-916. DOI: 10.1080/17512433.2018.1507735.
|
34. |
Gao S, Zhang Y, Li X, et al. Comparative efficacy of pharmacotherapy for macular edema secondary to retinal vein occlusion: a network meta-analysis[J/OL]. Front Pharmacol, 2021, 12: 752048[2021-12-08]. https://pubmed.ncbi.nlm.nih.gov/34955825/. DOI: 10.3389/fphar.2021.752048.
|
35. |
Liu W, Li Y, Cao R, et al. A systematic review and meta-analysis to compare the efficacy of Conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion[J/OL]. Medicine (Baltimore), 2020, 99(21): e20222[2020-05-22]. https://pubmed.ncbi.nlm.nih.gov/32481293/. DOI: 10.1097/MD.0000000000020222.
|
36. |
Deobhakta A, Chang LK. Inflammation in retinal vein occlusion[J/OL]. Int J Inflam, 2013, 2013: 438412[2013-04-03]. https://pubmed.ncbi.nlm.nih.gov/23653882/. DOI: 10.1155/2013/438412.
|
37. |
Massa H, Georgoudis P, Panos GD. Dexamethasone Intravitreal Implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature[J]. Ther Deliv, 2019, 10(6): 343-351. DOI: 10.4155/tde-2019-0024.
|
38. |
Aref AA, Scott IU, Oden NL, et al. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15[J]. JAMA Ophthalmol, 2015, 133(9): 1022-1029. DOI: 10.1001/jamaophthalmol.2015.1823.
|
39. |
Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117(6): 1134-1146. DOI: 10.1016/j.ophtha.2010.03.032.
|
40. |
Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results[J]. Ophthalmology, 2012, 119(1): 132-137. DOI: 10.1016/j.ophtha.2011.06.019.
|
41. |
Mushtaq Y, Mushtaq MM, Gatzioufas Z, et al. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the treatment of retinal conditions. A review of clinical studies[J]. Drug Des Devel Ther, 2023, 17: 961-975. DOI: 10.2147/DDDT.S403259.
|
42. |
Coelho J, Pessoa B, Meireles A. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)[J/OL]. Ther Adv Ophthalmol, 2019, 11: 2515841418820755[2019-01-05]. https://pubmed.ncbi.nlm.nih.gov/30643869/. DOI: 10.1177/2515841418820755.
|
43. |
The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion[J]. Ophthalmology, 1995, 102(10): 1425-1433. DOI: 10.1016/s0161-6420(95)30849-4.
|
44. |
中华医学会眼科学分会青光眼学组. 中国新生血管性青光眼诊疗专家共识(2019年)[J]. 中华眼科杂志, 2019, 55(11): 814-817. DOI: 10.3760/cma.j.issn.0412-4081.2019.11.005.Glaucoma Group, Society of Ophthalmology, Chinese Medical Association. Expert Consensus on Diagnosis and Treatment of neovascular glaucoma in China (2019)[J]. Chin J Ophthalmol, 2019, 55(11): 814-817. DOI: 10.3760/cma.j.issn.0412-4081.2019.11.005.
|
45. |
Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for central retinal vein occlusion: an evidence-based systematic review[J]. Ophthalmology, 2007, 114(3): 507-519, 524. DOI: 10.1016/j.ophtha.2006.11.011.
|
46. |
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion[J]. Am J Ophthalmol, 1984, 98(3): 271-282. DOI: 10.1016/0002-9394(84)90316-7.
|
47. |
McIntosh RL, Mohamed Q, Saw SM, et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review[J]. Ophthalmology, 2007, 114(5): 835-854. DOI: 10.1016/j.ophtha.2007.01.010.
|